Drugs / Adipose-derived mesenchymal cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02940418 Comparator | Feb 2017 → Nov 2019 | type 1 diabetes mellitus | Sophia Al-Adwan | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose-derived mesenchymal cells | “Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.” NCT02940418 ↗ |
| Modality | Cell therapy | “Allogenic adipose derived mesenchymal stem cells will be injected into patients newly diagnosed with type 1 Diabetes Mellitus” NCT02940418 ↗ |
| Route | Intravenous | “These cells will be injected intravenously into patients newly diagnosed with type 1 Diabetes Mellitus.” NCT02940418 ↗ |